^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Oligodendroglioma

    Related cancers:
    3d
    Ivosidenib and Vorasidenib decrease intratumoral 2-hydroxyglutarate and total choline levels in patients with lower-grade glioma: an in vivo MR Spectroscopy study. (PubMed, Clin Cancer Res)
    The striking reductions in tumor 2HG and tCho levels early following initiation of targeted therapy using an IDH inhibitor suggest that MRS may provide an important tool for monitoring treatment response of lower-grade gliomas.
    Preclinical • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    Tibsovo (ivosidenib) • Voranigo (vorasidenib)
    5d
    A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma (clinicaltrials.gov)
    P1, N=24, Recruiting, University of Nebraska | Trial completion date: Mar 2027 --> Jul 2029 | Trial primary completion date: Mar 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    temozolomide • abexinostat (CG-781)
    6d
    Immunohistochemical characterization of neural stem cells in brains of adult brachycephalic dogs in comparison with canine oligodendroglioma cells. (PubMed, J Vet Med Sci)
    We then examined canine oligodendroglioma tissues and found that tumor cells were immunopositive for SOX2, SOX9, and vimentin, similar to the immunophenotype of type B NSCs. These results indicate that brachycephalic adult dogs retain a higher number of NSCs with higher proliferative activity in the brain, which may create an environment prone to oligodendroglioma.
    Journal
    |
    SOX2 • VIM (Vimentin) • SOX9 (SRY-Box Transcription Factor 9) • PCNA (Proliferating cell nuclear antigen) • YBX1 (Y-Box Binding Protein 1)
    9d
    SERPINH1, a regulatory factor of oligodendroglioma cell invasion and extracellular matrix secretion, as a novel prognostic biomarker and therapeutic target. (PubMed, Transl Cancer Res)
    We found that SERPINH1 can serve as an independent prognostic biomarker for oligodendroglioma. It may be a potential new target for the treatment of oligodendroglioma.
    Journal
    |
    SERPINH1 (Serpin family H member 1)
    11d
    Seizure-presenting IDH-wildtype glioblastoma and the upregulation of a synaptic signature. (PubMed, J Neurosurg)
    In IDH-wildtype GBM, tumors presenting with seizures had smaller volumes than those presenting with other signs. Transcriptionally, seizure presentation in IDH-wildtype GBM correlated with the upregulation of synaptic and ionic pathways, with SLC17A8 holding independent predictive value for seizure presentation.
    Journal
    |
    CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • IGF1 (Insulin-like growth factor 1) • ADAMTS2 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 2)
    |
    IDH wild-type
    13d
    Role of Surrogate Immunohistochemistry Markers in CNS Tumors in the Era of Molecular Diagnostics With Recent Updates. (PubMed, Adv Anat Pathol)
    The review emphasizes that when interpreted alongside histomorphology and conventional markers, surrogate immunohistochemistry can significantly reduce reliance on molecular testing, expedite diagnosis, and improve accessibility of precision diagnostics. Standardization, validation, and awareness of pitfalls remain essential to maximizing their clinical utility in neuropathology practice.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ATRX (ATRX Chromatin Remodeler) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • BCOR (BCL6 Corepressor) • YAP1 (Yes associated protein 1) • VIM (Vimentin) • STAT6 (Signal transducer and activator of transcription 6) • L1CAM (L1 cell adhesion molecule) • DUX4 (Double Homeobox 4) • FOXR2 (Forkhead Box R2) • GAB1 (GRB2 Associated Binding Protein 1)
    |
    TP53 mutation • BRAF V600E • BRAF V600 • IDH mutation + BRAF V600E
    17d
    Transferrin Receptor 1 Overexpression Drives Proliferation and Ferroptosis Sensitivity in Glioblastoma: A Potential Therapeutic Vulnerability. (PubMed, Neuropathology)
    Ferroptosis induction by RSL3/FIN56 led to increased TFR1 expression and ROS generation...Temozolomide in combination with siRNA-mediated gene silencing showed a significantly higher antitumor effect than the drug or silencing alone. This may be one of the important therapeutic vulnerabilities of GBM. High TFR1 expression was associated with shorter overall survival in all gliomas together but not in GBM separately.
    Journal
    |
    TFRC
    |
    temozolomide • RSL3
    19d
    Acid Ceramidase Inhibition Disrupts Ceramide Homeostasis and Induces Mitochondrial Apoptosis in IDH1-Mutant Oligodendroglioma. (PubMed, Res Sq)
    These mechanistic effects translated into a survival benefit in oligodendroglioma xenograft-bearing mice. Together, these findings suggest that IDH1-mutant oligodendroglioma harbors a pre-existing heightened sensitivity to ceramide stress and identify acid ceramidase as a therapeutically actionable target in this disease.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 mutation
    24d
    Expanding the molecular grading criteria in IDH-mutant astrocytoma. (PubMed, Neuro Oncol)
    The presence of CDK4, CCND2, PDGFRA, PIK3R1, MYCN, and EGFR alterations result in an intermediate patient survival in IDH-mutant astrocytoma. Adding these molecular alterations should be considered in future diagnostic classification systems to improve stratification of high-risk patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TERT (Telomerase Reverse Transcriptase) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • CCND2 (Cyclin D2)
    |
    EGFR mutation • PIK3CA mutation • EGFR amplification • CDKN2A deletion • MYCN amplification • PDGFRA mutation
    25d
    Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas (clinicaltrials.gov)
    P1, N=36, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    |
    CLD-101
    25d
    From a Polymorphous Low-Grade Neuroepithelial Tumor to a Glioblastoma in an Adult Patient with FGFR3-TACC3 Fusion: A Case Report and Literature Review of the Molecular Profile. (PubMed, Curr Oncol)
    During follow-up, the patient underwent a second neurosurgery, where histological evaluation indicated a GMB. This article presents clinical and radiological data, morphology, immunohistochemistry, molecular features, and treatment to enhance the clinical and pathological understanding of PLNTY with FGFR3-TACC3 fusion for all professionals involved in medical decisions.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3) • ATRX (ATRX Chromatin Remodeler) • GFAP (Glial Fibrillary Acidic Protein) • OLIG2 (Oligodendrocyte Transcription Factor 2)
    |
    BRAF V600E • BRAF V600 • FGFR3-TACC3 fusion • FGFR fusion
    26d
    Delta-like ligand 3 expression in isocitrate dehydrogenase-mutant and isocitrate dehydrogenase-wildtype glioma is largely retained at recurrence, supporting its potential as a therapeutic target. (PubMed, Neurooncol Adv)
    DLL3 expression level is retained or increased in the majority of recurrent gliomas. Inclusion in trials with DLL3-targeting agents in recurrent glioma based on primary tumor material is justified, depending on the required level of DLL3 positivity for inclusion.
    Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression • DLL3 positive • IDH wild-type